Skip to main content

Table 5 Prevalence of different known side effects of DAA therapy among the studied group

From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus

Side effects

Number

Percent

Fatigue/asthenia

44

88.00

Anemia (Hb < 10 g/dl)

42

84.00

GIT upset

10

20.00

Psychiatric (sleep disorder)

8

16.00

Metabolic (decreased appetite)

8

16.00

Respiratory distress

6

12.00

Nervous system (headache/dizziness)

6

12.00

Musculoskeletal (muscle spasms)

4

8.00

Dermatologic (skin reactions/itching)

3

6.00

Hypersensitivity (angioedema)

0

0.00

Teratogenicity/embryo death

0

0.00

Drug interactions

0

0.00

Hepatic decompensation

0

0.00

Others

11

22.00